Loading clinical trials...
Loading clinical trials...
A Comparison of the Efficacy of Symbicort® Single Inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 Inhalation b.i.d. Plus As-needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults - a 26 Weeks, Randomised, Open-label, Parallel-group, Multicentre Study
Conditions
Interventions
Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy
Locations
53
Chile
Research Site
Quillota, Chile
Research Site
Valparaíso, Chile
Researh Site
Dubrovnik, Croatia
Research Site
Split, Croatia
Research Site
Zagreb, Croatia
Research Site
Brno, Czechia
Start Date
July 1, 2005
Completion Date
December 1, 2006
Last Updated
January 24, 2011
NCT02327897
NCT07219173
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions